Discover Afqlir®, a biosimilar medicine, part of the Sandoz biosimilar portfolio. 

Afqlir® is a recombinant fusion protein consisting of portions of human VEGF receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1.1 

Afqlir® acts as a soluble decoy receptor that binds VEGF-A and P1GF with higher affinity than their natural receptors, and thereby can inhibit the binding and activation of these cognate VEGF receptors.1

Afqlir®▼ (aflibercept)

Afqlir® is indicated for adults for the treatment of:1

  • Neovascular (wet) age-related macular degeneration (AMD) 

  • Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) 

  • Visual impairment due to diabetic macular oedema (DME) 

  • Visual impairment due to myopic choroidal neovascularisation (myopic CNV) 

Resources for you and your patients 

These resources have been specifically designed to help healthcare professionals provide their patients prescribed with Afqlir® the information and instruction they need to get the most from their treatment. 

PDF document titled 'Aflibercept 40 mg/mL injection' for healthcare professionals, showing drug details and usage information.

Healthcare Professional Guide 

A guide containing important information about storage and handling, administration instructions and safety considerations when using Afqlir®.

Download
Page with healthcare and medical product information, including sections about the medicinal product name, dosage, and ingredients, with some text highlighted in blue.

Summary of Product Characteristics

A document for prescribers, describing the properties and approved conditions of use for Afqlir®.

Download
Thumbnail for Afliir Administration Guide with a blue background and a play button icon in the center.

Administration video

A step-by-step instructional video to help familiarise you with the administration process for Afqlir®.

Watch
A medical PDF document titled 'Sandoz Patient Safety' about Afibrcept, a 40 mg/mL solution for injection, discussing active substance and product details.

Patient Guide

A guide for patients to help them understand what Afqlir® is, what to expect during their treatment and how to identify and report serious side effects. 

Download
Sandoz Patient Safety guide for Afrilcept 40mg/mL injection, blue background with white text and a white medical symbol.

Patient Audio Guide 

An audio version of the Patient Guide to ensure visually impaired patients have access to the same important information regarding their treatment with Afqlir®.

Listen
Download
A PDF document titled 'Package Leaflet: Information for the patient' about Afglir 40 mg/ml solution for injection in a pre-filled syringe. The document contains instructions, important safety information, and side effect reporting details.

Patient Information Leaflet 

A downloadable version of the leaflet that is included in every pack of Afqlir®, containing essential information on the medicine for patients.

Download

AMD, age-related macular degeneration; CNV, choroidal neovascularisation; DME, diabetic macular oedema; Fc, fragment crystallisable region; IgG1, immunoglobulin G1; P1GF, placental growth factor; RVO, retinal vein occlusion; VEGF, vascular endothelial growth factor. 

Reference

1. Afqlir® Summary of Product Characteristics [Accessed December 2025].

Adverse events should be reported. Reporting forms and information can be found on the HPRA website (www.hpra.ie) or by emailing Rowex adverse.event.ireland@sandoz.net

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Report any suspected adverse reactions via HPRA Pharmacovigilance; website: www.hpra.ie.

IE | December 2025 | MLR-0052-IE